Opinion and evidence in cardiovascular therapeutics

American Journal of Cardiovascular Drugs

Volumn 2, Issue 5, 2002, Pages 345-353

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMIODARONE; AMLODIPINE BESYLATE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CHLORHEXIDINE; CLOPIDOGREL; DALTEPARIN; DARUSENTAN; DILTIAZEM; DOBUTAMINE; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; IRBESARTAN; LEVOSIMENDAN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; ROXIFIBAN; SERTRALINE; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TIROFIBAN; UNINDEXED DRUG;

ARTICLE; BLEEDING; BREAST CANCER; CARDIOVASCULAR DISEASE; CATHETER INFECTION; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG EFFICACY; FATIGUE; FRACTURE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0036399634     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202050-00009     Document Type: Article

References (29)

1. Husted SE, Wallentin L, Lagerqvist B, et al. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J 2002; 23 (15): 1213-8
2. Verheugt FWA. Low molecular weight heparin: a bridge over troubled water. Eur Heart J 2002; 23 (15): 1144-6
3. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40: 231-7
4. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872-81
5. O'Grady NP, Alexander M, Patchen Dellinger E, et al. Guidelines for the prevention of intravascular catheter-related infections. MMWR Morbid Mortal Wkly Rep 2002; 51: 1-32
6. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-9
7. Carney RM, Jaffe AS. Treatment of depression following acute myocardial infarction. JAMA 2002; 288: 750-1
8. Wagner A, Herkner H, Schreiber W, et al. Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction. Thromb Haemost 2002; 88: 180-5
9. Kjeldsen SE, Hedner T, Syvertsen JO, et al. Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study. J Hyperten 2002; 20: 1231-7
10. Thijs L, Staessen JA, Wang J, et al. Subgroup analysis of the NORDIL trial. J Hyperten 2002; 20: 1085-7
11. Lemaitre RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidents from the Cardiovascular Health Study. Arch Intern Med 2002; 162: 1395-400
12. Grundy SM. Statin therapy in older persons: pertinent issues. Arch Intern Med 2002; 162: 1329-31
13. Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol 2002; 40: 49-55
14. Nakov R, Pfarr E, Eberle S, et al. Darusentan: an effective endothelin(A) receptor antagonist for treatment of hypertension. Am J Hyperten 2002; 15: (Pt 1) 583-9
15. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-9
16. Madrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-6
17. Moliterno DJ, Yakubov SJ, DiBattiste PM, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002; 360: 355-60
18. Roffi M, Moliterno DJ, Meier B, et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation 2002; 105: 2730-6
19. Stone GW, Moliterno DJ, Bertrand M, et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET trial. Circulation 2002; 105: 2347-54
20. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202
21. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351-7
22. Casciano R, Doyle JJ, Chen J, et al. Economic benefits of amlodipine treatment in patients with coronary artery disease. Pharmacoeconomics 2002; 20 (8): 553-63
23. Billheimer JT, Dicker IB, Wynn R, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002; 99: 3540-6
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33
26. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2-3
27. Compton A. A practical cost analysis of bivalirudin. Pharmacotherapy 2002; 22: 119S-27S
28. Newby LK, Califf RM, White HD, et al. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med 2002; 112: 647-58
29. Cannon CP. Oral glycoprotein IIb/IIIa inhibition - great idea, but it didn't work. Am J Med 112: 673-5